Singulex, Inc. is an innovative diagnostics company based in Hayward, California. They develop and commercialize direct molecular detection technology solutions that enable life science researchers and clinicians to understand and manage disease. Their biomarker diagnostic systems can detect and quantify normal and abnormal protein biomarkers. Singulex is currently conducting pilot studies to validate their digital molecule detection platform, the Erenna BioAssay System, which detects and quantifies molecule biomarkers in clinical samples. Additionally, they offer various custom assay services, including pilot study services, assay prototyping, characterization, and validation. Singulex is committed to improving patient care and reducing healthcare costs by providing high-value, advanced tests for the diagnosis and monitoring of chronic diseases.